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1. Introduction  
Phospholipase A2 (PLA2) catalyzes the hydrolysis of the SN-2 acyl ester linkage of 
phospholipids and producing fatty acids and lysophospholipids. Their activity is one of the 
rate-limiting steps in the formation of arachidonic acid and in the synthesis of leukotrienes 
and prostaglandins. These prostaglandins have vital role in carcinogenesis. In the present 
study structure based drug design approach has applied to the hnps-PLA2 inhibitors. It can 
be concluded that indole-3-acetamide derivative molecule 13 h was showing better 
interaction with the active site of hnps-PLA2. The comparative in silico ADME studies 
proved that 13h molecule could be a potential anticancer drug. Phospholipase is an enzyme 
that converts phospholipids into fatty acid and other lipophillic-substances. There are four 
major classes of Phospholipase, termed A, B, C and D. These classes are distinguished by the 
catalyzing type of reactions. Phospholipase A has two subtypes: Phospholipase A1 which 
cleaves the SN-1 acyl chain and Phospholipase A2 which cleaves the SN-2 acyl chain. 
2. Material and method 
Ligand fit (Discovery studio 2.1) software was used for molecular docking studies 
(Venkatachalam, C.M. et al. 2003). It is based on a cavity detection algorithm and Monte 
Carlo conformational search algorithm for generating ligand poses consistent with the 
active site shape. The crystal structure of hnps-PLA2 (1DB4) complex with potent indole 
inhibitor was determined and used in structure based drug design (Schevitz RW et al 
1995). The PDB structure 1DB4 was chosen for our study has 2.20 A° resolution and has 
RMSD value below 2 Aº. 
2.1 Ligand and receptor preparation 
The hnps-PLA2 inhibitors, 74 indole-3-acetic acid derivatives (Robert D. Dillard et al 1996) 
were sketched. The structure of all molecules used in the present study was designed on the 
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basis of the reported scaffold and the substituent table from NCBI pubchem. The Generic 
drugs with diverse scaffolds were downloaded from pubchem library. The Hydrogen Bonds 
were added and CHARMm force field was applied to all molecules. 
The crystal structure of hnps-PLA2 protein (1DB4) was downloaded from the PDB. After 
applying CHARMm force field macro molecule hnps-PLA2 was assigned as receptor. 
The receptor cavity was searched using flood filling algorithm and partition site was 
adjusted for the better fitments of molecule in the partition site of receptor. The 
comparative docking studies for all 100 molecules were performed. The determination of 
the ligand binding affinity was calculated using Ligscore1, Ligscore2 and Dock score 
were used to estimate the ligand-binding energies.In the present study ADME Tox 
software was used to study the toxicity of hnps-PLA2 inhibitors.We have used top ten 
ranked dock molecule of hnps-PLA2 for the present study.The Hydrogen Bonds were 
added and CHARMm force field was applied to all molecules and the ADME properties 
were calculated. 
3. Result and analysis 
In the present study we have taken generic drugs with diverse scaffolds and indole 
inhibitors of hnps- PLA2 which were biologically tested and synthesized (Robert D. Dillard 
et al 1996). The structure based studies of the molecules described above were carried out 
using Discovery Studio. The RMSD value between the top ten ranked (based on docked 
energy) reference molecules and hnp-SPLA2 was reported around 2Aº.  
Table 1 had shown the different score values of top ranked ligands against hnsp-SPLA2 
receptor. The score values include Ligscore1 and Ligscore 2 which is based on protein-
ligand affinity energy (Krammer et al 2005). It has been observed that Ligscore1 (6.16), 
Ligscore2 (7.06) were found highest for the 13 h molecule in comparison with the other 100 
molecules. During the study it has been observed that molecule 13 h which was found 
highest docked energy score 80.47 has high inhibitory concentration (IC50 .03 uM) which 
proved that the drugs found most effective in prior experimental studies was also giving 
high dock scores.  
It has been reported that indole inhibitors when substituted with additional alkyl group at 
different positions of indole the efficacy of the compound had increased towards hnps-PLA2 
(Lin et al 2003). In the present study the molecules having indole ring proved more efficient 
when substituting with other additional groups on indole ring. In comparison with the 
binding affinity of the other molecules it has been observed that indole-3- derivatives were 
found most effective scaffold. The top 7 Ranked docked molecules had indole ring and a 
additional acid side chain on the fifth position with acid group (13h (80.47 J/mol), 41 (71.59 
J/mol), 2n (70.59 J/mol), 71 (70.48 J/mol), 7i (68.14 J/mol), 16b (67.71 J/mol), 60a (67.71 
J/mol) ) It has been observed that indole-3-acetamides series molecule possessed potency 
and selectivity as inhibitors of hnps-PLA2 (Robert D. Dillard et al 1996). It was observed that 
the top 6 docked molecules (molecule 13h (80.47 J/mol), 41 (71.59 J/mol), 71 (70.48 J/mol), 
7i (68.14 J/mol), 16b (67.71 J/mol), 60a (67.71 J/mol) ) had 3-acetamide side chain at Indole 
ring. The molecule 13 h had oxy propyl phosphonic acid group on fifth position which had 
shown strong hydrogen bonding formation with the active site residue histidine of hnp-
SPLA2 receptor.(Fig 1). 
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Fig. 1. Molecule 13h showing hydrogen bonding with histidine 
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Fig. 2. Molecule 13h 
www.intechopen.com
Design of Human Non-Pancreatic Secretary  
Phospholipase A2 (hnps-PLA2) Inhibitors: A Structure Based Molecule Design Approach 
 
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Molecule 41 showing similarties with mol 13h 
The structural similarity of two top ranked dock score molecules suggested that both had 
3-indole acetamide ring as basic scaffold and phosphonic acid group which was attached 
to fifth position of indole and a benzyl ring which was attached to first position of 
indole.(Fig 2,3) 
The top ten ranked dock molecules were chosen for ADME analysis. The ADME properties 
of 13h were found very satisfactory. The aqueous solubility value was found within optimal 
range-(4.028) whereas the molecule indomethcin (3.24), indoprofen (3.54) was found not 
good solubility value. The molecule 16b, 7i, 71, 60a had poor (3) intestinal absorption level 
whereas molecule 13 h had very good (0) intestinal absorption level. The Plasma protein 
binding was found more than  90% for molecule 13 h  but it was reported more than 95% for 
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the molecule 41 and 2n. The Blood Brain Penetration Level for molecule 13h was found to be 
extremely low (4) level and the cytochrome P450 enzyme (1) level was not found to be 
inhibited by molecule 13 h. Thus comparing with the other molecules ADME properties 13 h 
had a good therapeutic index. 
 
 
 
 
 
 
 
Name LigScore1 LigScore2 DOCK_SCORE
13h 6.16 7.06 80.47 
Bendazac 2.79 2.97 71.766 
41 6 6.62 71.496 
2n 3.33 2.89 70.596 
71 5.64 6.39 70.48 
7i 6.14 6.27 68.147 
16b 4.27 5.19 67.71 
60a 4.88 6.63 67.487 
Indometacin 3.54 4.26 66.921 
Indoprofen 2.86 2.85 66.375 
13f 5.81 6.9 65.9 
4n 4.76 5.46 65.728 
7o 5.47 5.84 65.64 
7r 5.32 6.4 65.526 
 
 
 
 
 
 
 
 
Table 1. Sketched molecules with Best dock score 
4. Conclusion 
In the present study it can be concluded that Indole derivative molecule 13 h is proved to 
better molecule in terms of experimental studies, molecular interaction with hnp-SPLA2 
receptor and computational ADME studies. So the present study proved that hnps-PLA2 
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based inhibitor molecule 13 h (Fig 4) could be a better substitute for NSAID (Non-steroid 
anti inflammatory drug).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Showing alternate pathway for inflammation 
5. References  
Robert D. Dillard & Nicholas. (1996). Indole Inhibitors of Human Nonpancreatic Secretory 
Phospholipase A2. Indole-3-acetamides with Additional Functionality. J. Med. 
Chem, Vol 39, pp. 5137–5158. 
Robert D. Dillard & Nicholas. (1996). Indole Inhibitors of Human Nonpancreatic Secretory 
Phospholipase A2. Indole-3-acetamides. J. Med. Chem, Vol.39, pp. 5119–5136. 
Lars Linderoth & Thomas L. (2008). Molecular Basis of Phospholipase A2 Activity toward 
Phospholipids  with sn-1 Substitutions. Biophys J. Vol 94, pp. 14–26 
Venkatachalam CM & Jiang.(2003) LigandFit: A Novel Method for the Shape-Directed Rapid 
Docking of Ligands to Protein Active Sites.J Mol Graph Modell, Vol 21, pp. 289-307. 
www.intechopen.com
 
Inflammatory Diseases – A Modern Perspective 
 
24
Krammer A & Kirchhoff PD. (2005) LigScore: a novel scoring function for predicting binding 
affinities. J Mol Graph Model, Vol 23, pp. 395-407. 
Schevitz RW & Bach NJ. (1995). Structure-based design of the first potent and selective 
inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol., Vol 
2, pp .458-65. 
www.intechopen.com
Inflammatory Diseases - A Modern Perspective
Edited by Dr. Amit Nagal
ISBN 978-953-307-444-3
Hard cover, 240 pages
Publisher InTech
Published online 16, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
"Inflammatory Diseases - A Modern Perspective" represents an extended and thoroughly revised collection of
papers on inflammation. This book explores a wide range of topics relevant to inflammation and inflammatory
diseases while its main objective is to help in understanding the molecular mechanism and a concrete review
of inflammation. One of the interesting things about this book is its diversity in topics which include
pharmacology, medicine, rational drug design, microbiology and biochemistry. Each topic focuses on
inflammation and its related disease thus giving a unique platform which integrates all the useful information
regarding inflammation.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Amit Nagal (2011). Design of Human Non-Pancreatic Secretary Phospholipase A2 (hnps-PLA2) Inhibitors: A
Structure Based Molecule Design Approach, Inflammatory Diseases - A Modern Perspective, Dr. Amit Nagal
(Ed.), ISBN: 978-953-307-444-3, InTech, Available from: http://www.intechopen.com/books/inflammatory-
diseases-a-modern-perspective/design-of-human-non-pancreatic-secretary-phospholipase-a2-hnps-pla2-
inhibitors-a-structure-based-mol
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
